Aalborg, Denmark: The consumption of synthetic CBD is not associated with clinically significant reductions in pain intensity in patients with either hand osteoarthritis or psoriatic arthritis, according to clinical trial data published in the journal Pain.
Dutch investigators evaluated the efficacy of the daily use of synthetic CBD versus placebo for 12 weeks in 129 patients with arthritis. Subjects in the study consumed CBD (or placebo) as an adjunct to their regularly prescribed medications.
“We found neither clinically nor statistically significant effect of CBD for pain intensity in patients with hand osteoarthritis and psoriatic arthritis when compared to placebo,” authors reported. “Additionally, no statistically significant effects were found on sleep quality, depression, anxiety, or pain catastrophizing scores.”
Patients with arthritis often report using cannabis therapeutically. However, relatively few controlled studies are available assessing the use of either cannabis or cannabinoids in patients with RA and the results of these trials have been inconsistent.
Full text of the study, “Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial,” appears in Pain. Additional information regarding the use of cannabinoids for arthritis is available from NORML.